secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2024-01-03T23:59:59+00:00
Accession:  0001213900-24-000858
Event type: leadership
Sentiment:  negative
Materiality: 0.70
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Relmada Therapeutics CMO Cedric O'Gorman departs effective Jan 3, 2024
----------------------------------------------------------------------

- Dr. Cedric O'Gorman concluded his role as Chief Medical Officer on January 3, 2024, by mutual agreement.
- No successor or interim CMO has been announced by the company.
- CMO departure creates uncertainty for Relmada's clinical development programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390024000858/0001213900-24-000858-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390024000858/ea191111-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-000858

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer